This content is intended for healthcare professionals only.

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.
Login
Don't have an account yet? Register now
Lost your password? Reset password
OR
Login with DocCheck Login with Linkedin
Access as a guest
Choose Language
English
English
https://beigenemedical.info/search/ESMO/
Italian
https://beigenemedical.info/it/search/ESMO/
French
https://beigenemedical.info/fr/search/ESMO/
Spanish
https://beigenemedical.info/es/search/ESMO/
German
https://beigenemedical.info/de/search/ESMO/
I am not a Healthcare Professional

Please login or register for full access

Register
Already registered? Login
Skip to content
Choose Language
English
English
English
Italian
Italian
French
French
Spanish
Spanish
German
German
Login / Register
  • Congresses
    • Congress Calendar
    • Virtual Congress
  • BeiGeneius
  • Pipelines
Choose Language
English
English
English
Italian
Italian
French
French
Spanish
Spanish
German
German

ESMO

European Society for Medical Oncology
All Types
All Types
Reading
reading
Slide-Kit
slidekit
Video
video
Latest
Latest
latest
Oldest
oldest
All Types
All Types
Reading
reading
Slide-Kit
slidekit
Video
video
Latest
Latest
latest
Oldest
oldest
Suggested:
CLL
EHA
ESMO
Hematologic malignancies
Solid tumor
WM
BeiGene

Sitravatinib plus tislelizumab in patients with metastatic NSCLC

Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with metastatic non-small cell lung cancer (NSCLC).

Reading
28 Apr 2022
NSCLC
Tislelizumab
ESMO
Please login or register to access the download
BeiGene

Sitravatinib + tislelizumab in patients with anti-PD-(L)1 R/R metastatic NSCLC

Results from a multi-cohort phase 1b trial where stravatinib in combination with tislelizumab is currently being investigated in patients with anti-PD-(L)1 refractory/resistant (R/R) metastatic non-small cell lung cancer (NSCLC).

Reading
28 Apr 2022
NSCLC
Tislelizumab
ESMO
Please login or register to access the download
memo

Memo inOncology - ESMO 2021 congress report

Report on treatment advances in advanced solid tumors presented at ESMO 2021.

Reading
15 Dec 2021
ESMO
Solid tumor
Tislelizumab
memo

Memo inOncology - WCLC and ESMO 2021 congress report

Report on updates in the treatment of lung cancer presented at WCLC and ESMO 2021.

Reading
15 Dec 2021
ESMO
WCLC
Lung cancer
memo

Memo inOncology - ESMO 2021 congress report

Report on updates in the treatment of lung and gastrointestinal cancers presented at ESMO 2021.

Slide-Kit
15 Dec 2021
ESMO
Solid tumor
Tislelizumab
Load More

This website contains information for a broad scientific audience and may include information on products or indications that are not licensed, approved, or accessible in your country or region. Prescribing information or other medical information for products may also differ between countries or regions. Please visit beigene.com for more information.

As part of scientific exchange, BeiGene is providing the most recent abstract(s) accepted by the referenced scientific congress. The scientific information may include data/information on investigational use(s) of compounds/drugs that efficacy and safety have not been established. Information available on this webportal is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of BeiGene products.​

  • About Us
  • Privacy Policy
  • Terms & Conditions
  • Legal notice

waldenstroms.info

memo inOncology

© BeiGene 2022. All rights reserved.   |   Cookie Settings

You're now leaving the website beigenemedical.info

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beigenemedical.info website. The link will take you to another BeiGene website, the content of which is subject to the locally applicable laws and regulations.

BeGene Switzerland GmbH makes no representation that the information provided on the website is suitable or available for use or access in locations outside the country for which the website is intended.

Please ensure that you belong to the target group of the content provided on the linked website and that your access to it complies with the applicable laws and regulations.

No, I want to go back Yes, I would like to continue

You're now leaving the website beigenemedical.info

This link is provided for information purposes only. Please be aware that, if you click on it, you will leave beigenemedical.info website. The link will take you to a website owned and operated by an independent party over which BeiGene Switzerland GmbH has no control or influence (“third-party website”).​

BeiGene Switzerland GmbH makes no representation that information on the third-party website is appropriate or available for use or access in locations outside the country for which the third-party website is intended. Therefore, BeiGene Switzerland GmbH declines any responsibility for third-party information. BeiGene Switzerland GmbH makes no representation regarding the data usage policies of the third party website and declines any responsibility for the use of personal data by the operator of the third-party website. Please ensure that you belong to the intended audience of the content provided on third-party website and that your access to it complies with the applicable laws and regulations.

Do you really want to leave the beigenemedical.info website?

No, I want to go back Yes, I would like to continue